KR102410503B1 - 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법 - Google Patents

안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법 Download PDF

Info

Publication number
KR102410503B1
KR102410503B1 KR1020200050837A KR20200050837A KR102410503B1 KR 102410503 B1 KR102410503 B1 KR 102410503B1 KR 1020200050837 A KR1020200050837 A KR 1020200050837A KR 20200050837 A KR20200050837 A KR 20200050837A KR 102410503 B1 KR102410503 B1 KR 102410503B1
Authority
KR
South Korea
Prior art keywords
weight
formulation
weight percent
chloride
points
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020200050837A
Other languages
English (en)
Korean (ko)
Other versions
KR20200128629A (ko
Inventor
티나 드브리스
데이비드 제이콥스
Original Assignee
알브이엘 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알브이엘 파마슈티컬즈, 인크. filed Critical 알브이엘 파마슈티컬즈, 인크.
Publication of KR20200128629A publication Critical patent/KR20200128629A/ko
Priority to KR1020220072209A priority Critical patent/KR102663319B1/ko
Application granted granted Critical
Publication of KR102410503B1 publication Critical patent/KR102410503B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020200050837A 2019-05-06 2020-04-27 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법 Active KR102410503B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020220072209A KR102663319B1 (ko) 2019-05-06 2022-06-14 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962844069P 2019-05-06 2019-05-06
US201962843819P 2019-05-06 2019-05-06
US62/844,069 2019-05-06
US62/843,819 2019-05-06
US16/716,014 2019-12-16
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
US16/715,998 2019-12-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020220072209A Division KR102663319B1 (ko) 2019-05-06 2022-06-14 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20200128629A KR20200128629A (ko) 2020-11-16
KR102410503B1 true KR102410503B1 (ko) 2022-06-17

Family

ID=72750169

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020200050837A Active KR102410503B1 (ko) 2019-05-06 2020-04-27 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법
KR1020220072209A Active KR102663319B1 (ko) 2019-05-06 2022-06-14 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법
KR1020240057166A Active KR102859351B1 (ko) 2019-05-06 2024-04-29 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020220072209A Active KR102663319B1 (ko) 2019-05-06 2022-06-14 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법
KR1020240057166A Active KR102859351B1 (ko) 2019-05-06 2024-04-29 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법

Country Status (16)

Country Link
US (11) US10814001B1 (https=)
EP (1) EP3965737A1 (https=)
JP (3) JP7141420B2 (https=)
KR (3) KR102410503B1 (https=)
CN (2) CN111888326B (https=)
AU (1) AU2020268329B2 (https=)
BR (1) BR112021022404A2 (https=)
CL (1) CL2021002918A1 (https=)
CO (1) CO2021015265A2 (https=)
IL (1) IL287831A (https=)
MA (1) MA55895A (https=)
MX (1) MX2021013516A (https=)
PE (1) PE20220384A1 (https=)
SG (1) SG11202112272TA (https=)
WO (1) WO2020227260A1 (https=)
ZA (2) ZA202108950B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
WO2022187306A1 (en) 2021-03-03 2022-09-09 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114521A1 (en) * 2008-03-11 2009-09-17 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
WO2010141831A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
JP2002249445A (ja) 2000-12-19 2002-09-06 Ophtecs Corp 眼科用液剤組成物
US6806364B2 (en) 2002-07-29 2004-10-19 Ast Products, Inc. Ophthalmic compositions
CN101327325A (zh) * 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
DE10337186A1 (de) 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
AU2007227091B2 (en) 2006-03-17 2013-02-07 Johnson & Johnson Vision Care, Inc. Stabilized ophthalmic compositions comprising oxidatively unstable components
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
WO2008070185A2 (en) * 2006-12-06 2008-06-12 The Trustees Of Columbia University In The City Of New York Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
WO2009061431A2 (en) 2007-11-08 2009-05-14 Aciex Therapeutics, Inc. Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
BRPI0821647A2 (pt) 2007-12-21 2015-06-16 Schering Plough Healthcare Realce da fotosestabillização de oximetazolina
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
AU2011327785A1 (en) * 2010-11-08 2013-03-07 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
US8883838B2 (en) 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
CA2833420C (en) 2011-04-26 2019-09-03 Rdd Pharma Ltd. Oxymetazoline for the treatment of ano-rectal disorders
JP2015518006A (ja) 2012-05-25 2015-06-25 エクスクリア インコーポレイテッド キシリトール系の抗粘膜組成物及び関連する方法並びに組成物
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
CN106034406B (zh) 2013-09-18 2019-09-10 迈康尼股份公司 对smt系统操作员提供信息的方法、系统和设备
AU2015274532B2 (en) 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses
EP3302426A4 (en) 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
CN108883308A (zh) 2016-01-26 2018-11-23 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114521A1 (en) * 2008-03-11 2009-09-17 Alcon Research, Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
WO2010141831A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same

Also Published As

Publication number Publication date
US20230355587A1 (en) 2023-11-09
CL2021002918A1 (es) 2022-08-19
US20210386711A1 (en) 2021-12-16
US10898573B1 (en) 2021-01-26
KR20200128629A (ko) 2020-11-16
CN111888326B (zh) 2023-07-21
US11701343B2 (en) 2023-07-18
KR102663319B1 (ko) 2024-05-03
US20240033250A1 (en) 2024-02-01
US11103482B2 (en) 2021-08-31
US11541036B2 (en) 2023-01-03
US11324722B2 (en) 2022-05-10
US20210212992A1 (en) 2021-07-15
EP3965737A1 (en) 2022-03-16
SG11202112272TA (en) 2021-12-30
ZA202108950B (en) 2023-10-25
CN117045596A (zh) 2023-11-14
AU2020268329B2 (en) 2026-01-15
JP7141420B2 (ja) 2022-09-22
KR102859351B1 (ko) 2025-09-12
IL287831A (en) 2022-01-01
US20220273621A1 (en) 2022-09-01
CA3139443A1 (en) 2020-11-12
US20210137889A1 (en) 2021-05-13
NZ782902A (en) 2024-09-27
WO2020227260A1 (en) 2020-11-12
US20220257566A1 (en) 2022-08-18
US11311515B2 (en) 2022-04-26
JP2021191802A (ja) 2021-12-16
MX2021013516A (es) 2022-01-24
JP7705326B2 (ja) 2025-07-09
KR20240060580A (ko) 2024-05-08
BR112021022404A2 (pt) 2022-01-18
AU2020268329A1 (en) 2022-01-06
PE20220384A1 (es) 2022-03-18
US20200353083A1 (en) 2020-11-12
ZA202212328B (en) 2025-03-26
US12605363B2 (en) 2026-04-21
US20210015795A1 (en) 2021-01-21
KR20220084264A (ko) 2022-06-21
US10940138B2 (en) 2021-03-09
US10799481B1 (en) 2020-10-13
CO2021015265A2 (es) 2022-02-28
JP2020183373A (ja) 2020-11-12
US20210023222A1 (en) 2021-01-28
JP2025065198A (ja) 2025-04-17
US10814001B1 (en) 2020-10-27
CN111888326A (zh) 2020-11-06
MA55895A (fr) 2022-03-16

Similar Documents

Publication Publication Date Title
KR102859351B1 (ko) 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법
EP3463360B1 (en) Atropine-containing aqueous composition
CA3139443C (en) Oxymetazoline compositions and methods for treating ocular disorders
RU2820596C2 (ru) Композиции оксиметазолина и способы для лечения офтальмологических расстройств
HK40100508A (zh) 羟甲唑啉组合物和用於治疗眼障碍的方法
HK40031931B (zh) 羟甲唑啉组合物和用於治疗眼障碍的方法
HK40031931A (en) Oxymetazoline compositions and methods for treating ocular disorders
BR122024023871A2 (pt) Formulações livres de conservantes oftálmicas aquosas farmaceuticamente estáveis, recipientes de uso único, bem como usos terapêuticos das ditas formulações
EA044560B1 (ru) Водная композиция, содержащая атропин

Legal Events

Date Code Title Description
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0107 Divisional application

St.27 status event code: A-0-1-A10-A18-div-PA0107

St.27 status event code: A-0-1-A10-A16-div-PA0107

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4